487-52-5
基本信息
紫铆查尔酮
BUTEIN
BUTANOL
BUTEIN(P)
BUTEIN(SH)
BUTEIN WITH HPLC
Einecs 207-659-5
2',3,4,4'-TETRAHYDROCHALCONE
3,4,2',4'-TETRAHYDROXYCHALCONE
2',4',3,4-TETRAHYDROXYCHALCONE
2',3,4,4'-TETRAHYDROXYCHALCONE
2',3,4,4'-Tetrahydroxy-trans-chalcone
Butein 2',3,4,4'-Tetrahydroxychalcone
1-(2,4-DIHYDROXYPHENYL)-3-(3,4-DIHYDROXYPHENYL)-2-PROPEN-1-ONE
1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propene-1-one
(E)-1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one
2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-, (2E)-
(E)-1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one 2',3,4,4'-Tetrahydroxychalcone
物理化学性质
| 熔点 | 216°C |
| 沸点 | 560.9±50.0 °C(Predicted) |
| 密度 | 1.483±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | DMSO: >50 mg/mL |
| 酸度系数(pKa) | 7.44±0.35(Predicted) |
| 形态 | solid |
| 形态 | 固体 |
| 颜色 | yellow |
| 颜色 | 黄色 |
| LogP | 2.405 (est) |
| CAS 数据库 | 487-52-5(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P305+P351+P338 |
| 安全说明 | S22-S24/25 |
| WGK Germany | 3 |
| 海关编码 | 29145090 |
应用领域
知名试剂公司产品信息
紫铆因价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/11/08 | B3803 | 紫铆因 Butein | 487-52-5 | 100mg | 610元 |
| 2024/11/08 | B3803 | 紫铆因 Butein | 487-52-5 | 1g | 2990元 |
常见问题列表
|
EGFR 16 μM (IC 50 , in HepG2 cells) |
PDE4 10.4 μM (IC 50 ) |
Butein potently inhibits cAMP-specific phosphodiesterase (type IV) activity with an IC
50
of 10.4±0.4 μM. In contrast, phosphodiesterase I, III and V activities were inhibited by Butein above 100 μM.
Butein, a plant polyphenol, is a specific protein tyrosine kinase inhibitor. Butein inhibits not only the EGF-stimulated auto-phosphotyrosine level of EGFR in HepG2 cells but also tyrosine-specific protein kinase activities of EGFR (IC
50
=16 μM) and p60
c-src
(IC
50
=65 μM) in vitro.
Butein (10, 20, and 40 μM; 24, 48, and 72 hours) inhibits cell growth in a dose- and time-dependent manner.
Butein exhibits anticancer activity through the inhibition of the activation of PKB/AKT and MAPK pathways, which are two pathways known to be involved in resistance to cisplatin. Butein (20 µM) decreases phosphorylation of AKT, ERK and p38 following 24 h of co-treatment with Cisplatin (20 µM).
Cell Viability Assay
| Cell Line: | HeLa cells |
| Concentration: | 10, 20, and 40 μM |
| Incubation Time: | 24, 48, and 72 hours |
| Result: | Inhibited cell growth in a dose- and time-dependent manner. |
Western Blot Analysis
| Cell Line: | HeLa cells |
| Concentration: | 20 µM |
| Incubation Time: | 24 hours |
| Result: | Decreased phosphorylation of AKT, ERK and p38 co-treatment with Cisplatin (20 µM). |
Butein (2 mg/kg every 2 days) in combination with Cisplatin (2 mg/kg every 2 days) for 3 weeks suppresses tumor growth in vivo.
| Animal Model: | Nude mice (12 female 6- or 7-week old) with subcutaneous tumor xenografts |
| Dosage: | 2 mg/kg |
| Administration: | Intraperitoneally; every 2 days; for 3 weeks |
| Result: | Enhanced the antitumor effects of Cisplatin in vivo. |